NCT07185243View on ClinicalTrials.gov

A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

recombinant human IL-21-expressing oncolytic vaccinia virus injection

hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.

Trial Locations (1)

361000

RECRUITING

Xiamen Humanity Hospital, Xiamen

All Listed Sponsors
collaborator

Xiamen Humanity Hospital

OTHER

lead

Hangzhou Converd Co., Ltd.

INDUSTRY

NCT07185243 - A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter